Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $68.91 USD
Change Today -0.74 / -1.06%
Volume 2.5M
BAX On Other Exchanges
Symbol
Exchange
New York
Berlin
SIX Swiss Ex
Mexico
As of 8:04 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX) Snapshot

Open
$69.96
Previous Close
$69.65
Day High
$69.99
Day Low
$68.68
52 Week High
07/23/14 - $77.31
52 Week Low
02/20/15 - $65.94
Market Cap
37.5B
Average Volume 10 Days
2.6M
EPS TTM
$4.38
Shares Outstanding
544.3M
EX-Date
05/28/15
P/E TM
15.7x
Dividend
$2.08
Dividend Yield
3.02%
Current Stock Chart for BAXTER INTERNATIONAL INC (BAX)

baxter international inc (BAX) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX) Details

Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products. The Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; and products and services related to pharmacy compounding, drug formulation and packaging technologies, as well as to treat renal disease, irreversible kidney failures, and other renal therapies. This segment also offers products for peritoneal dialysis, in-center and home hemodialysis, continuous renal replacement therapy, and other dialysis services. It markets its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and patients. The company operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. It has collaboration with Merrimack Pharmaceuticals, Inc. to develop and commercialize MM-398 injection; CTI BioPharma Corp. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products; and Onconova Therapeutics, Inc. for rigosertib anti-cancer compound. The company was founded in 1931 and is based in Deerfield, Illinois.

66,000 Employees
Last Reported Date: 02/26/15
Founded in 1931

baxter international inc (BAX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $755.0K
Corporate Vice President and President of Bio...
Total Annual Compensation: $833.8K
Corporate Vice President, General Counsel and...
Total Annual Compensation: $651.0K
Corporate Vice President of Human Resources
Total Annual Compensation: $525.3K
Compensation as of Fiscal Year 2014.

baxter international inc (BAX) Key Developments

Baxter International Inc. Declares Quarterly Dividend, Payable on July 1, 2015

The Board of Directors of Baxter International Inc. declared a quarterly dividend of $0.52 per Baxter common share. This cash dividend is payable on July 1, 2015 to shareholders of record as of June 1, 2015.

Baxter International Inc. Files Marketing Authorization Application to the European Medicines Agency for Approval of MM-398

Baxter International Inc. and Merrimack Pharmaceuticals Inc. jointly announced that Baxter has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for approval of MM-398 (irinotecan liposome injection), also known as ''nal-IRI,'. The submission follows Merrimack’s recent filing of a new drug application (NDA) for this indication with the United States Food and Drug Administration (FDA). Both the U.S. and European submissions were based on the positive results of the international Phase 3 NAPOLI-1 study, which was conducted among patients with metastatic pancreatic cancer who previously received gemcitabine-based therapy. MM-398 in combination with 5-fluorouracil (5-FU) and leucovorin (LV) achieved its primary and secondary endpoints by demonstrating a clinically and statistically significant improvement in overall survival, progression free survival and overall response rate compared to the control group of patients who received a combination of 5-FU and LV. The most common Grade 3 or higher adverse events in patients receiving MM-398 and 5-FU/LV were neutropenia, fatigue and gastrointestinal effects. This was the first global Phase 3 study in a post-gemcitabine setting to show a survival benefit in this aggressive disease. MM-398 (irinotecan liposome injection), also known as "nal-IRI," is a novel encapsulation of irinotecan in a long-circulating nanoliposomal formulation. The activated form of irinotecan is SN-38, which functions by inhibiting topoisomerase I (an essential enzyme involved in DNA transcription and replication) and promoting cell death.

Merrimack Pharmaceuticals and Baxter Announces Completion of New Drug Application Submission to U.S. FDA for MM-398 as Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer

Merrimack Pharmaceuticals, Inc. and Baxter International Inc. jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration (FDA). Merrimack is seeking U.S. marketing approval of MM-398 for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. The companies also announced that Merrimack has requested priority review of the MM-398 NDA by the FDA. Merrimack's application is based upon the results of an international Phase 3 study (NAPOLI-1) conducted in patients with metastatic pancreatic cancer who previously received gemcitabine-based therapy. MM-398 in combination with 5-fluorouracil (5-FU) and leucovorin achieved its primary and secondary endpoints by demonstrating a statistically significant improvement in overall survival, progression free survival and overall response rate compared to the control group of patients who received a combination of 5-FU and leucovorin. The most common Grade 3 or higher adverse events in patients receiving MM-398 and 5-FU/LV were neutropenia, fatigue and gastrointestinal effects. This was the first global Phase 3 study in a post-gemcitabine setting to show a survival benefit in this aggressive disease. The data were previously presented in June 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX:US $68.91 USD -0.74

BAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,825 JPY -50.00
Kimberly-Clark Corp $109.86 USD +0.46
Mylan NV $71.05 USD -1.84
Stryker Corp $92.56 USD -0.34
Takeda Pharmaceutical Co Ltd ¥6,171 JPY -22.00
View Industry Companies
 

Industry Analysis

BAX

Industry Average

Valuation BAX Industry Range
Price/Earnings 20.5x
Price/Sales 2.3x
Price/Book 4.7x
Price/Cash Flow 16.0x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit www.baxter.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.